Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0041-1735978
Hyperhomocysteinemia and Ischemic Stroke: A Potential Dose-Response Association—A Systematic Review and Meta-analysis
Funding This study was supported by grants from Redordati Rare Diseases. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or manuscript preparation.![](https://www.thieme-connect.de/media/10.1055-s-00033990/202103/lookinside/thumbnails/10-1055-s-0041-1735978_210037-1.jpg)
Abstract
Background and Purpose Previous studies suggest an association between increased homocysteine (Hcy) and risk of ischemic stroke. Yet, it remains unknown whether a dose-response association exists between Hcy levels and risk of ischemic stroke.
Methods Systematic literature searches were performed in PubMed, Embase, Scopus, and Web of Science. Inclusion criteria were studies investigating ischemic stroke risk in an adult population with measured Hcy levels. We computed odds ratios (ORs) for a 5 µmol/L increase in Hcy levels using a random effects meta-analysis.
Results In total, 108 studies met the inclusion criteria of which 22 were rated as high-quality studies, and 20 studies included a dose-response analysis. Hcy levels were analyzed either as a continuous or categorical variable. The majority of the studies found an increased risk of ischemic stroke when comparing the highest-to-lowest Hcy strata. A graded association was observed over the Hcy strata, indicating a dose-response association, with the most apparent effect when Hcy levels exceeded approximately 15 µmol/L. No studies explored a potential nonlinear association between Hcy levels and ischemic stroke. Six studies were included in a meta-analysis, showing an OR of 1.43 (95% confidence interval [CI]: 1.28–1.61) per 5 µmol/L increase in Hcy levels.
Conclusion This review and meta-analysis indicate a dose-response association between Hcy levels and ischemic stroke. An evident increase in effect measures was observed when Hcy levels exceeded 15 µmol/L, indicating a nonlinear association between ischemic stroke and Hcy levels. This nonlinear association warrants further study.
This study is registered with clinical trial ( https://www.crd.york.ac.uk/prospero/ ; unique identifier: CRD42019130371).
Publication History
Received: 07 May 2021
Accepted: 19 July 2021
Article published online:
24 September 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 McCully KS. Atherogenesis and the chemical pathology of homocysteine. European Journal of Laboratory Medicine 1996; 4: 121-128
- 2 Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338 (15) 1042-1050
- 3 Ansari R, Mahta A, Mallack E, Luo JJ. Hyperhomocysteinemia and neurologic disorders: a review. J Clin Neurol 2014; 10 (04) 281-288
- 4 Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62
- 5 Faraci FM, Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke 2004; 35 (02) 345-347
- 6 Ungvari Z, Csiszar A, Edwards JG. et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003; 23 (03) 418-424
- 7 Eberhardt RT, Forgione MA, Cap A. et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000; 106 (04) 483-491
- 8 Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354 (9176): 407-413
- 9 Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994; 25 (10) 1924-1930
- 10 Alfthan G, Pekkanen J, Jauhiainen M. et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106 (01) 9-19
- 11 Ebbing M, Bønaa KH, Arnesen E. et al. Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials. J Intern Med 2010; 268 (04) 367-382
- 12 Toole JF, Malinow MR, Chambless LE. et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291 (05) 565-575
- 13 Huo Y, Li J, Qin X. et al; CSPPT Investigators. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 2015; 313 (13) 1325-1335
- 14 Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2017; 8: CD006612
- 15 Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325 (7374): 1202
- 16 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
- 17 National Heart Lung, and Blood Institute. Study quality assessment tools. Accessed September 6, 2021 at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
- 18 Iso H, Moriyama Y, Sato S. et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004; 109 (22) 2766-2772
- 19 Cui R, Moriyama Y, Koike KA. et al; JACC Study group. Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis 2008; 198 (02) 412-418
- 20 Haltmayer M, Mueller T, Lange W. et al. Relation between homocysteine and non-fatal stroke in peripheral arterial disease. Eur J Neurol 2002; 9 (06) 609-614
- 21 Fallon UB, Virtamo J, Young I. et al. Homocysteine and cerebral infarction in finnish male smokers. Stroke 2003; 34 (06) 1359-1363
- 22 Loffredo L, Violi F, Fimognari FL. et al. The association between hyperhomocysteinemia and ischemic stroke in patients with non-valvular atrial fibrillation. Haematologica 2005; 90 (09) 1205-1211
- 23 Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31 (05) 1069-1075
- 24 Atanassova PA, Angelova E, Tzvetanov P, Semerdjieva M, Dimitrov BD. Modelling of increased homocysteine in ischaemic stroke: post-hoc cross-sectional matched case-control analysis in young patients. Arq Neuropsiquiatr 2007; 65 (01) 24-31
- 25 Bosco P, Guéant-Rodriguez RM, Anello G. et al. Association of homocysteine (but not of MTHFR 677 C>T, MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischaemic cerebrovascular disease in Sicily. Thromb Haemost 2006; 96 (02) 154-159
- 26 Delport R, Ubbink JB, Vermaak WJ, Rossouw H, Becker PJ, Joubert J. Hyperhomocysteinaemia in black patients with cerebral thrombosis. QJM 1997; 90 (10) 635-639
- 27 Haapaniemi E, Helenius J, Soinne L, Syrjälä M, Kaste M, Tatlisumak T. Serial measurements of plasma homocysteine levels in early and late phases of ischemic stroke. Eur J Neurol 2007; 14 (01) 12-17
- 28 Hassan A, Hunt BJ, O'Sullivan M. et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004; 127 (pt. 1): 212-219
- 29 Kara N, Senes M, Coskun O, Inan L, Saydam G, Yucel D. Urinary methylmalonic acid levels in patients with acute ischemic stroke. Clin Biochem 2009; 42 (7,8): 578-583
- 30 Kario K, Duell PB, Matsuo T. et al. High plasma homocyst(e)ine levels in elderly Japanese patients are associated with increased cardiovascular disease risk independently from markers of coagulation activation and endothelial cell damage. Atherosclerosis 2001; 157 (02) 441-449
- 31 Kelly PJ, Kistler JP, Shih VE. et al. Inflammation, homocysteine, and vitamin B6 status after ischemic stroke. Stroke 2004; 35 (01) 12-15
- 32 Kim MH, Moon JS, Park SY. et al. Different risk factor profiles between silent brain infarction and symptomatic lacunar infarction. Eur Neurol 2011; 65 (05) 250-256
- 33 Kim OJ, Hong SH, Oh SH. et al. Association between VEGF polymorphisms and homocysteine levels in patients with ischemic stroke and silent brain infarction. Stroke 2011; 42 (09) 2393-2402
- 34 Kristensen B, Malm J, Nilsson TK. et al. Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. Stroke 1999; 30 (05) 974-980
- 35 Kucukarabaci B, Gunes HV, Ozdemir G. et al. Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke. Genet Test 2008; 12 (03) 443-451
- 36 Lee JH, Kim OJ, Kim HS. et al. Polymorphisms of thymidylate synthase enhancer region (TSER) and upstream stimulatory factor 1 (USF1 306G > A) genes are associated with plasma homocysteine level and susceptibility to ischemic stroke in a Korean population. Genes Genomics 2008; 30: 563-570
- 37 Lehmann MF, Kallaur AP, Oliveira SR. et al. Inflammatory and metabolic markers and short-time outcome in patients with acute ischemic stroke in relation to TOAST subtypes. Metab Brain Dis 2015; 30 (06) 1417-1428
- 38 Li G, Liu Y, Li X. et al. Association of pai-1 4g/5g polymorphism with ischemic stroke in Chinese patients with type 2 diabetes mellitus. Genet Test Mol Biomarkers 2018; 22 (09) 554-560
- 39 Lindgren A, Brattström L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995; 26 (05) 795-800
- 40 Lu SJ, Zhou XS, Zheng Q, Chen HL, Geng YL. Platelet membrane receptor P2Y12 H1/H2 polymorphism is highly associated with cerebral infarction: a case-control study. Neuropsychiatr Dis Treat 2018; 14: 2225-2231
- 41 Luo HC, Luo QS, Wang CF, Lei M, Li BL, Wei YS. Association of miR-146a, miR-149, miR-196a2, miR-499 gene polymorphisms with ischemic stroke in a Chinese people. Oncotarget 2017; 8 (46) 81295-81304
- 42 Ma L, Jiang Y, Kong X. et al. Synergistic effect of the MTHFR C677t and EPHX2 G860A polymorphism on the increased risk of ischemic stroke in Chinese type 2 diabetic patients. J Diabetes Res 2017; 2017: 6216205
- 43 Ma SG, Xu W, Wei CL. et al. Role of ischemia-modified albumin and total homocysteine in estimating symptomatic lacunar infarction in type 2 diabetic patients. Clin Biochem 2011; 44 (16) 1299-1303
- 44 Mao X, Han L. The relationship of methylenetetrahydrofolate reductase gene C677T polymorphism and ischemic stroke in Chinese Han population. Ann Clin Lab Sci 2018; 48 (02) 242-247
- 45 Meiklejohn DJ, Vickers MA, Dijkhuisen R, Greaves M. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001; 32 (01) 57-62
- 46 Mejia Mohamed EH, Tan KS, Ali JM, Mohamed Z. TT genotype of the methylenetetrahydrofolate reductase C677T polymorphism is an important determinant for homocysteine levels in multi-ethnic Malaysian ischaemic stroke patients. Ann Acad Med Singap 2011; 40 (04) 186-191
- 47 Modi M, Prabhakar S, Majumdar S, Khullar M, Lal V, Das CP. Hyperhomocysteinemia as a risk factor for ischemic stroke: an Indian scenario. Neurol India 2005; 53 (03) 297-301 , discussion 301–302
- 48 Moe KT, Woon FP, De Silva DA. et al. Association of acute ischemic stroke with the MTHFR C677T polymorphism but not with NOS3 gene polymorphisms in a Singapore population. Eur J Neurol 2008; 15 (12) 1309-1314
- 49 Mojiminiyi OA, Marouf R, Al Shayeb AR. et al. Determinants and associations of homocysteine and prothrombotic risk factors in Kuwaiti patients with cerebrovascular accident. Med Princ Pract 2008; 17 (02) 136-142
- 50 Parnetti L, Caso V, Santucci A. et al. Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Neurol Sci 2004; 25 (01) 13-17
- 51 Perini F, Galloni E, Bolgan I. et al. Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: stronger association with small artery disease. Neurol Sci 2005; 26 (05) 310-318
- 52 Pezzini A, Del Zotto E, Archetti S. et al. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke. Stroke 2002; 33 (03) 664-669
- 53 Press RD, Beamer N, Evans A, DeLoughery TG, Coull BM. Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke. Diagn Mol Pathol 1999; 8 (01) 54-58
- 54 Rahman A, Gupta RD, Quraishi FA, Saha UK, Miah MNA, Ali Z. Relationship between homocysteine and ischemic stroke. Journal of Medicine (Bangladesh) 2013; 14: 47-51
- 55 Tantirittisak T, Sura T, Moleerergpoom W, Hanchaipiboolkul S. Plasma homocysteine and ischemic stroke patients in Thailand. J Med Assoc Thai 2007; 90 (06) 1183-1187
- 56 Ustundag M, Orak M, Guloglu C, Ozturk E, Tamam Y, Kale E. The role of serum ferritin, pro-brain natriuretic peptide and homocysteine levels in determining ischaemic stroke subtype, severity and mortality. Hong Kong J Emerg Med 2010; 17: 13-21
- 57 Vayá A, Ejarque I, Tembl J, Corella D, Laiz B. Hyperhomocysteinemia, obesity and cryptogenic stroke. Clin Hemorheol Microcirc 2011; 47 (01) 53-58
- 58 Wang C, Han L, Wu Q. et al. Association between homocysteine and incidence of ischemic stroke in subjects with essential hypertension: a matched case-control study. Clin Exp Hypertens 2015; 37 (07) 557-562
- 59 Wang CY, Chen ZW, Zhang T. et al. Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients. Eur J Intern Med 2014; 25 (06) 538-544
- 60 Xia XS, Li X, Wang L, Wang JZ, Ma JP, Wu CJ. Supplementation of folic acid and vitamin B12 reduces plasma levels of asymmetric dimethylarginine in patients with acute ischemic stroke. J Clin Neurosci 2014; 21 (09) 1586-1590
- 61 Yadav BK, Yadav R, Chang H. et al. Genetic polymorphisms rs699947, rs1570360, and rs3025039 on the VEGF gene are correlated with extracranial internal carotid artery stenosis and ischemic stroke. Ann Clin Lab Sci 2017; 47 (02) 144-155
- 62 Yang TH, Chang CY, Hu ML. Various forms of homocysteine and oxidative status in the plasma of ischemic-stroke patients as compared to healthy controls. Clin Biochem 2004; 37 (06) 494-499
- 63 Yang Z, Wang L, Zhang W, Wang X, Zhou S. Plasma homocysteine involved in methylation and expression of thrombomodulin in cerebral infarction. Biochem Biophys Res Commun 2016; 473 (04) 1218-1222
- 64 Yao Y, Gao LJ, Zhou Y. et al. Effect of advanced age on plasma homocysteine levels and its association with ischemic stroke in non-valvular atrial fibrillation. J Geriatr Cardiol 2017; 14 (12) 743-749
- 65 Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998; 29 (12) 2478-2483
- 66 Zhang F, Li X, Dong Q, Wang Y, Zhang H. Risk of acute cerebral infarction and plasma asymmetrical dimethylarginine and homocysteine levels: a clinical correlation analysis of Chinese population. J Stroke Cerebrovasc Dis 2014; 23 (09) 2225-2232
- 67 Zhang H, Zhao X, Wang C. et al. A preliminary study of the association between apolipoprotein e promoter methylation and atherosclerotic cerebral infarction. J Stroke Cerebrovasc Dis 2019; 28 (04) 1056-1061
- 68 Zhu F, Jin XP, Zhu M. et al. Matrix metalloproteinase 10 gene polymorphism and atherothrombotic cerebral infarction risk in a Han Chinese population. Int J Clin Exp Med 2013; 6 (07) 567-575
- 69 Adunsky A, Weitzman A, Fleissig Y. et al. The relation of plasma total homocysteine levels to prevalent cardiovascular disease in older patients with ischemic stroke. Aging (Milano) 2000; 12 (01) 48-52
- 70 Akpalu A, Nyame P. Plasma homocysteine as a risk factor for strokes in ghanaian adults. Ghana Med J 2009; 43 (04) 157-163
- 71 Al-Allawi NA, Avo AS, Jubrael JM. Methylenetetrahydrofolate reductase C677T polymorphism in Iraqi patients with ischemic stroke. Neurol India 2009; 57 (05) 631-635
- 72 Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989; 79 (2,3): 139-146
- 73 Salem-Berrabah OB, Mrissa R, Machghoul S. et al. Hyperhomocysteinemia, C677T MTHFR polymorphism and ischemic stroke in Tunisian patients. Tunis Med 2010; 88 (09) 655-659
- 74 Brattström L, Lindgren A, Israelsson B. et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992; 22 (03) 214-221
- 75 Celikbilek A, Ismailogullari S, Zararsiz G. Neutrophil to lymphocyte ratio predicts poor prognosis in ischemic cerebrovascular disease. J Clin Lab Anal 2014; 28 (01) 27-31
- 76 Cingozbay BY, Yiginer O, Cebeci BS, Kardesoglu E, Demiralp E, Dincturk M. Role of homocysteine for thromboembolic complication in patients with non-valvular atrial fibrilation. Blood Coagul Fibrinolysis 2002; 13 (07) 609-613
- 77 Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21 (04) 572-576
- 78 El Kossi MM, Zakhary MM. Oxidative stress in the context of acute cerebrovascular stroke. Stroke 2000; 31 (08) 1889-1892
- 79 Fatima S, Memon SF, Ansari AK, Baloch AH. Hyperhomocystenemia as a risk factor for ischemic stroke. J Liaquat Uni Med Health Sci 2012; 11: 158-161
- 80 Fekih-Mrissa N, Mrad M, Klai S. et al. Methylenetetrahydrofolate reductase (C677T and A1298C) polymorphisms, hyperhomocysteinemia, and ischemic stroke in Tunisian patients. J Stroke Cerebrovasc Dis 2013; 22 (04) 465-469
- 81 Karakurum Goksel B, Karatas M, Nebioglu A. et al. Subclinical hypothyroidism, hyperhomocysteinemia and dyslipidemia: investigating links with ischemic stroke in Turkish patients. Neurol Res 2007; 29 (08) 871-876
- 82 Han SC, Guo Y, Sun GJ, Gu YY. Relation of plasma homocysteine with folic acid and vitamine b12 in patients with cerebral infarction. Zhongguo Linchuang Kangfu 2002; 6: 2970-2971
- 83 Karabulut KU, Bayir A, Kara F, Ak A. The levels of serum b12, folic acid and homocysteine in the thromboembolic diseases. J Clin Anal Med 2017; 8: 130-133
- 84 Kokocińska D, Cierpka L, Chmiel B. et al. The usefulness of assessing the serum levels of homocysteine in diagnosis of atherosclerosis. Acta Angiologica 2005; 11: 114-120
- 85 Li FS, Luo XW, Jia LH. et al. Relativity of the type and grade of stroke with the serum homocysteine level. Zhongguo Linchuang Kangfu 2004; 8: 1974-1975
- 86 Liu JG, Zhang ZC, Gao HF, Liu HX, Tan XM. Relationship between hyperhomocysteinemia and cerebral stroke in young and middle-aged people. Zhongguo Linchuang Kangfu 2005; 9: 221-223
- 87 Moghaddasi M, Mamarabadi M, Mirzadeh S, Freydoonnejad AA, Razjouyan H. Homocysteine, vitamin B12 and folate levels in Iranian patients with ischemic stroke. Neurol Res 2010; 32 (09) 953-956
- 88 Mykhalojko OJ, Mykhalojko IJ. Some biochemical changes in patients with acute ischemic stroke. Ukr Biochem J 2017; 89: 31-35
- 89 Narang AP, Verma I, Kaur S, Narang A, Gupta S, Avasthi G. Homocysteine–risk factor for ischemic stroke?. Indian J Physiol Pharmacol 2009; 53 (01) 34-38
- 90 Omrani HQ, Shandiz EE, Qabai M, Chaman R, Fard HA, Qaffarpoor M. Hyperhomocysteinemia, folateo and B12 vitamin in Iranian patients with acute ischemic stroke. ARYA Atheroscler 2011; 7 (03) 97-101
- 91 Peng H, Huang Q, Li Y. et al. Study on the relationship between plasma homocysteine and acute cerebral vascular disease. J Tongji Med Univ 2000; 20 (04) 330-331
- 92 Sawuła W, Banecka-Majkutewicz Z, Kadziński L. et al. Homocysteine level and metabolism in ischemic stroke in the population of Northern Poland. Clin Biochem 2009; 42 (06) 442-447
- 93 Sönmezler A, Ulaş T, Dal MS, Demir ME, Karababa IF, Büyükhatipoǧlu H. Plasma homocysteine levels in patients with acute ischemic stroke: A cross-sectional study. Turkiye Klinikleri Journal of Medical Sciences 2013; 33: 384-388
- 94 Sun JZ, Xu Y, Lu H, Zhu Y. Polymorphism of the methylenetetrahydrofolate reductase gene association with homocysteine and ischemic stroke in type 2 diabetes. Neurol India 2009; 57 (05) 589-593
- 95 Sun WP, Zhao JX, Wan Q, Wei D, Yu YX. Association of hyperhomocysteinemia and methylenetetrahydrofolate reductase gene polymorphisms with ischemic stroke in northwest Chinese population. Zhongguo Linchuang Kangfu 2005; 9: 171-173
- 96 Tas A, Tas F, Candan F, Topaktas S. Association between homocysteine level and intima-media thickness in patients with first ischemic stroke. Neurol Psychiatry Brain Res 2005; 12: 53-58
- 97 Unal E, Mungan S, Bilen S. et al. The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke. Int J Neurosci 2013; 123 (08) 532-536
- 98 Urbańska EM, Luchowski P, Luchowska E. et al. Serum kynurenic acid positively correlates with cardiovascular disease risk factor, homocysteine: a study in stroke patients. Pharmacol Rep 2006; 58 (04) 507-511
- 99 Wei W, Chen X, Lin X. et al. Serum PPARγ level and PPARγ gene polymorphism as well as severity and prognosis of brain injury in patients with arteriosclotic cerebral infarction. Exp Ther Med 2018; 16 (05) 4058-4062
- 100 Wu GH, Kong FZ, Dong XF. et al. Association between hyperhomocysteinemia and stroke with atherosclerosis and small artery occlusion depends on homocysteine metabolism-related vitamin levels in Chinese patients with normal renal function. Metab Brain Dis 2017; 32 (03) 859-865
- 101 Yi L, Huang Y, Wu T, Wu J. A magnetic nanoparticles-based method for DNA extraction from the saliva of stroke patients. Neural Regen Res 2013; 8 (32) 3036-3046
- 102 Yingdong Z, Zhigang Z, Yang L. Association of plasma homocysteine level and N5,N10-methylenetetrahydrofolate reductase gene polymorphism with cerebral infarction. Chin Med Sci J 2002; 17 (04) 231-235
- 103 Zhang W, Zhang X. Correlation between the youth cerebral infarction in different TOAST classifications and high homocysteine. Cell Biochem Biophys 2015; 71 (01) 39-42
- 104 Zhou J, Zhang SZ, Zhang Y, Chen Z, Ding MP. Relationship between plasma homocysteine level and stroke. Zhongguo Linchuang Kangfu 2005; 9: 181-183
- 105 Tanne D, Haim M, Goldbourt U. et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003; 34 (03) 632-636
- 106 Shimizu H, Kiyohara Y, Kato I. et al. Plasma homocyst(e)ine concentrations and the risk of subtypes of cerebral infarction. The Hisayama study. Cerebrovasc Dis 2002; 13 (01) 9-15
- 107 Tascilar N, Ekem S, Aciman E. et al. Hyperhomocysteinemia as an independent risk factor for cardioembolic stroke in the Turkish population. Tohoku J Exp Med 2009; 218 (04) 293-300
- 108 Tan NC, Venketasubramanian N, Saw SM, Tjia HT. Hyperhomocyst(e)inemia and risk of ischemic stroke among young Asian adults. Stroke 2002; 33 (08) 1956-1962
- 109 Khan U, Crossley C, Kalra L. et al. Homocysteine and its relationship to stroke subtypes in a UK black population: the south London ethnicity and stroke study. Stroke 2008; 39 (11) 2943-2949
- 110 Campbell DJ, Woodward M, Chalmers JP. et al. Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. Arch Neurol 2006; 63 (01) 60-65
- 111 Hultdin J, Van Guelpen B, Winkvist A. et al. Prospective study of first stroke in relation to plasma homocysteine and MTHFR 677C>T and 1298A>C genotypes and haplotypes - evidence for an association with hemorrhagic stroke. Clin Chem Lab Med 2011; 49 (09) 1555-1562
- 112 Kaplan RC, McGinn AP, Baird AE. et al. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study. J Stroke Cerebrovasc Dis 2008; 17 (06) 344-355
- 113 Rueda-Clausen CF, Córdoba-Porras A, Bedoya G. et al. Increased plasma levels of total homocysteine but not asymmetric dimethylarginine in Hispanic subjects with ischemic stroke FREC-VI sub-study. Eur J Neurol 2012; 19 (03) 417-425
- 114 Liang Y, Chen P, Sun Y, Feng P, Huang B, Jiang T. Evaluation of laboratory parameters in predicting ischemic stroke in essential hypertension patients. Biomedical Research (India) 2017; 28: 4013-4019
- 115 Li Z, Sun L, Zhang H. et al; Multicenter Case-Control Study in China. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China. Stroke 2003; 34 (09) 2085-2090
- 116 Shi Z, Liu S, Guan Y. et al. Changes in total homocysteine levels after acute stroke and recurrence of stroke. Sci Rep 2018; 8 (01) 6993
- 117 Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348 (9035): 1120-1124
- 118 Bostom AG, Rosenberg IH, Silbershatz H. et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999; 131 (05) 352-355
- 119 Zee RY, Mora S, Cheng S. et al. Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem 2007; 53 (05) 845-851
- 120 Schindler K, Zauner C, Buchmayer H. et al. High prevalence of hyperhomocysteinemia in critically ill patients. Crit Care Med 2000; 28 (04) 991-995
- 121 Lonn E, Held C, Arnold JM. et al; HOPE-2 Investigators. Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Can J Cardiol 2006; 22 (01) 47-53
- 122 Spence JD. Homocysteine-lowering therapy: a role in stroke prevention?. Lancet Neurol 2007; 6 (09) 830-838
- 123 Sterne JA, Sutton AJ, Ioannidis JP. et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002
- 124 Kong X, Huang X, Zhao M. et al. Platelet count affects efficacy of folic acid in preventing first stroke. J Am Coll Cardiol 2018; 71 (19) 2136-2146
- 125 Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346 (8987): 1395-1398
- 126 Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998; 18 (12) 1895-1901
- 127 Sahebkar A, Pirro M, Reiner Ž. et al. A systematic review and meta-analysis of controlled trials on the effects of statin and fibrate therapies on plasma homocysteine levels. Curr Med Chem 2016; 23 (39) 4490-4503
- 128 Cao L, Guo Y, Zhu Z. Study of the inflammatory mechanisms in hyperhomocysteinemia on large-artery atherosclerosis based on hypersensitive c-reactive protein-a study from southern china. J Stroke Cerebrovasc Dis 2019; 28 (07) 1816-1823
- 129 Dai Z, Jiao Y, Fan Q, Qi A, Xiao L, Li J. Homocysteine, interleukin-1β, and fasting blood glucose levels as prognostic markers for diabetes mellitus complicated with cerebral infarction and correlated with carotid intima-media thickness. Exp Ther Med 2020; 19 (02) 1167-1174
- 130 Wei GJ, Yuan MQ, Jiang LH. et al. A genetic variant of mir-34a contributes to susceptibility of ischemic stroke among Chinese population. Front Physiol 2019; 10: 432
- 131 Alkali NH, Watt H, Bwala SA, Gadzama A. Association of plasma homocysteine and ischaemic stroke in a nigerian population. Pakistan J Med Sci 2006; 22: 405-408